On June 24, the French drugmaker said that late-stage data from Sanofi and GlaxoSmithKline’s experimental Covid-19 vaccine showed it could protect against the Omicron variant of the vaccine.

The vaccine targets the Beta variant, originally discovered in South Africa and the original Wuhan strain of the virus.
In a trial involving 13,000 adults, the vaccine was 64.7% effective against symptomatic COVID patients at the first dose and 72% effective against infections caused by the Omicron variant.

“Sanofi-GSK’s vaccine is the first vaccine candidate to demonstrate efficacy in a placebo-controlled trial in a high Omicron variant circulating environment,” Sanofi said in a statement.

The companies said Friday that new data supporting the vaccine would be submitted to regulators to provide it later this year.